Le nirsevimab a permis de réduire les infections par le virus respiratoire syncytial nécessitant des soins médicaux chez des nourrissons prématurés en bonne santé dans le cadre d’un essai de phase IIb

NEXT STORY
BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature
PREV STORY
Tiziana Life Sciences to Participate in Investor Webinar to Provide Corporate Updates and Q&A Session on July 30, 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals’ Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.

Chicago, IL, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty ...

author_avatar
NASDAQ Market News

AroCell AB (publ) Year-End Report 2018

author_avatar
NASDAQ Market News

Immunovaccine and UConn Health Extend Collaboration to Support Advancement of Patient-Specific Immunotherapies to the Clinic

HALIFAX, Nova Scotia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (“Immunovaccine” or the ...

author_avatar
NASDAQ Market News